BRCA1 and BRCA2 germline pathogenic variants are a matter of concern because of their relevance in cancer risk assessment, personalized treatment options, and cancer prevention. Therefore, the study of quality of life (QoL), although complex, has been a challenge for clinical care and research implications for patients and families with hereditary breast and ovarian cancer (HBOC). This chapter aims to show the evolution of the evaluation of the QoL study according to the current needs of patients with BRCA1/BRCA2 mutations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.